Siegel CA - Search Results

1

Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model.

Siegel CA, Finlayson SR, Sands BE, Tosteson AN. Siegel CA, et al. Clin Gastroenterol Hepatol. 2012 Jan;10(1):46-51. doi: 10.1016/j.cgh.2011.09.017. Epub 2011 Oct 1. Clin Gastroenterol Hepatol. 2012. PMID: 21963958 Free PMC article.

2

When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations.

Siegel CA, Schwartz LM, Woloshin S, Cole EB, Rubin DT, Vay T, Baars J, Sands BE. Siegel CA, et al. Inflamm Bowel Dis. 2010 Oct;16(10):1658-62. doi: 10.1002/ibd.21233. Inflamm Bowel Dis. 2010. PMID: 20186940 Free PMC article.

3

Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease.

Siegel CA, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, Leleiko N, Mack DR, Crandall W, Evans J, Keljo DJ, Otley AR, Oliva-Hemker M, Farrior S, Langton CR, Wrobel IT, Wahbeh G, Quiros JA, Silber G, Bahar RJ, Sands BE, Dubinsky MC. Siegel CA, et al. Among authors: siegel ls. Inflamm Bowel Dis. 2011 Jan;17(1):30-8. doi: 10.1002/ibd.21386. Epub 2010 Sep 1. Inflamm Bowel Dis. 2011. PMID: 20812335 Free PMC article.

4

Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management.

Johnson FR, Hauber B, Özdemir S, Siegel CA, Hass S, Sands BE. Johnson FR, et al. Among authors: siegel ca. J Manag Care Pharm. 2010 Oct;16(8):616-28. doi: 10.18553/jmcp.2010.16.8.616. J Manag Care Pharm. 2010. PMID: 20866166 Free PMC article.

5

What options do we have for induction therapy for Crohn's disease?

Siegel CA. Siegel CA. Dig Dis. 2010;28(3):543-7. doi: 10.1159/000320414. Epub 2010 Sep 30. Dig Dis. 2010. PMID: 20926884 Free PMC article.

6

Translating improved quality of care into an improved quality of life for patients with inflammatory bowel disease.

Siegel CA, Allen JI, Melmed GY. Siegel CA, et al. Clin Gastroenterol Hepatol. 2013 Aug;11(8):908-12. doi: 10.1016/j.cgh.2013.05.027. Epub 2013 Jun 5. Clin Gastroenterol Hepatol. 2013. PMID: 23747710 Review.

7

Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease.

Dulai PS, Siegel CA, Dubinsky MC. Dulai PS, et al. Among authors: siegel ca. Inflamm Bowel Dis. 2013 Dec;19(13):2927-36. doi: 10.1097/MIB.0b013e31829aad16. Inflamm Bowel Dis. 2013. PMID: 23867874 Free PMC article. Review.

8

Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.

Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Dulai PS, et al. Among authors: siegel ca. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1443-51; quiz e88-9. doi: 10.1016/j.cgh.2014.01.021. Epub 2014 Jan 22. Clin Gastroenterol Hepatol. 2014. PMID: 24462626 Review.

9

Beware of the swinging pendulum: anti-tumor necrosis factor monotherapy vs combination therapy for inflammatory bowel disease.

Bressler B, Siegel CA. Bressler B, et al. Among authors: siegel ca. Gastroenterology. 2014 Apr;146(4):884-7. doi: 10.1053/j.gastro.2014.02.018. Epub 2014 Feb 25. Gastroenterology. 2014. PMID: 24576727 No abstract available.

10

Patient decision tools in inflammatory bowel disease.

Siegel CA. Siegel CA. Gastroenterol Hepatol (N Y). 2013 Sep;9(9):585-7. Gastroenterol Hepatol (N Y). 2013. PMID: 24729767 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

225 results

Search Page

Filters